Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of WID-CLZ18 vs Clozaril in Schizophrenia
NCT04849026Phase 1Completed
- Sponsor
- WhanIn Pharm
- Start
- Jan 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of WID-CLZ18 in schizophrenia (2 arms), sponsored by WhanIn Pharm. Primary endpoints: Maximum Observed Plasma Concentration up to 12 hours and Area Under the Curve 0-12 hours. Started Jan 2021; status: completed.
02
Drugs
WID-CLZ18
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04849026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849026.